In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Kato, Takamitsu A ^a,b,c   Tsuda, Akihisa ^a,b,d   Uesaka, Mitsuru ^d   Fujimori, Akira ^a,b   Kamada, Tadashi ^a   Tsujii, Hirohiko ^a   Okayasu, Ryuichi ^a,b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CAMPTOTHECIN; CARBON; CISPLATIN; HEAVY ION; IRON; MITOMYCIN C; PROTEIN P53; ANTINEOPLASTIC AGENT; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE; CELL GROWTH; CELL KILLING; CELL STRAIN U CH1; CELL STRAIN U87 MG; CELL SURVIVAL; CHORDOMA; CHROMOSOME NUMBER; CONTROLLED STUDY; DNA CONTENT; GLIOBLASTOMA; HEAVY ION RADIATION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; RELATIVE BIOLOGIC EFFECTIVENESS; UTERINE CERVIX CANCER; BIOSYNTHESIS; BONE TUMOR; CHROMOSOME; FLOW CYTOMETRY; KARYOTYPING; REPRODUCIBILITY; TIME; TUMOR CELL LINE; ULTRASTRUCTURE; X RAY;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CHORDOMA; CHROMOSOMES; FLOW CYTOMETRY; HELA CELLS; HUMANS; KARYOTYPING; RELATIVE BIOLOGICAL EFFECTIVENESS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; X-RAYS;

EID: 80052655562     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-116     Document Type: Article

References (40)

1. Azzarelli A, Quagliuolo V, Cerasoli S, Zucali R, Bignami P, Mazzaferro V, Dossena G, Gennari L. Chordoma: natural history and treatment results in 33 cases. J Surg Oncol 1988, 37(3):185-191. 10.1002/jso.2930370311, 3352273.
2. Sundaresan N, Galicich JH, Chu FC, Huvos AG. Spinal chordomas. J Neurosurg 1979, 50(3):312-319. 10.3171/jns.1979.50.3.0312, 422982.
3. Catton C, O'Sullivan B, Bell R, Laperriere N, Cummings B, Fornasier V, Wunder J. Chordoma: long-term follow-up after radical photon irradiation. RadiotherOncol 1996, 41(1):67-72.
4. Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC. Lumbosacral chordoma. Prognostic factors and treatment. Spine (Phila Pa 1976) 1999, 24(16):1639-1645.
5. Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jakel O, Jensen A, Klemm S, Munter M, Naumann J, Nikoghosyan A, Oertel S, Parodi K, Rieken S, Debus J. Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta Oncol 2010, 49(7):1132-1140. 10.3109/0284186X.2010.498432, 20831505.
6. Fagundes MA, Hug EB, Liebsch NJ, Daly W, Efird J, Munzenrider JE. Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys 1995, 33(3):579-584. 10.1016/0360-3016(95)02014-3, 7558946.
7. Henderson FC, McCool K, Seigle J, Jean W, Harter W, Gagnon GJ. Treatment of chordomas with CyberKnife: georgetown university experience and treatment recommendations. Neurosurgery 2009, 64(2 Suppl):A44-A53.
8. Imai R, Kamada T, Tsuji H, Sugawara S, Serizawa I, Tsujii H, Tatezaki S. Effect of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and Phase II clinical trials. Int J Radiat Oncol Biol Phys 2010, 77(5):1470-1476. 10.1016/j.ijrobp.2009.06.048, 19939576.
9. Imai R, Kamada T, Tsuji H, Yanagi T, Baba M, Miyamoto T, Kato S, Kandatsu S, Mizoe JE, Tsujii H, Tatezaki S. Carbon ion radiotherapy for unresectable sacral chordomas. Clin Cancer Res 2004, 10(17):5741-5746. 10.1158/1078-0432.CCR-04-0301, 15355901.
10. Schoenthaler R, Castro JR, Petti PL, Baken-Brown K, Phillips TL. Charged particle irradiation of sacral chordomas. Int J Radiat Oncol Biol Phys 1993, 26(2):291-298. 10.1016/0360-3016(93)90209-E, 8491686.
11. Schulz-Ertner D, Nikoghosyan A, Didinger B, Karger CP, Jakel O, Wannenmacher M, Debus J. Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions. Phys Med Biol 2003, 48(16):2617-2631. 10.1088/0031-9155/48/16/304, 12974578.
12. Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jakel O, Karger C, Scholz M, Kraft G, Wannenmacher M, Debus J. Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients. Strahlenther Onkol 2003, 179(9):598-605. 10.1007/s00066-003-1120-2, 14628125.
13. Sciubba DM, Chi JH, Rhines LD, Gokaslan ZL. Chordoma of the spinal column. Neurosurg Clin N Am 2008, 19(1):5-15. 10.1016/j.nec.2007.09.006, 18156043.
14. Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, Leu KM, Chandler WF, Baker LH. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. JClinOncol 2005, 23(15):3597-3604.
15. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006, 29(12):572-574. 10.1159/000096283, 17202828.
16. Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirabosco R, Flanagan AM. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 2009, 100(9):1406-1414. 10.1038/sj.bjc.6605019, 2694420, 19401700.
17. Rhomberg W, Bohler FK, Novak H, Dertinger S, Breitfellner G. A small prospective study of chordomas treated with radiotherapy and razoxane. Strahlen ther Onkol 2003, 179(4):249-253.
18. Scheil S, Bruderlein S, Liehr T, Starke H, Herms J, Schulte M, Moller P. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 2001, 32(3):203-211. 10.1002/gcc.1184, 11579460.
19. Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka T, Furusawa Y, Ando K, Suzuki M, Soga F, Kawachi K. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 1999, 44(1):201-210. 10.1016/S0360-3016(98)00544-6, 10219815.
20. Kanai T, Furusawa Y, Fukutsu K, Itsukaichi H, Eguchi-Kasai K, Ohara H. Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy. Radiat Res 1997, 147(1):78-85. 10.2307/3579446, 8989373.
21. Kanai T, Matsufuji N, Miyamoto T, Mizoe J, Kamada T, Tsuji H, Kato H, Baba M, Tsujii H. Examination of GyE system for HIMAC carbon therapy. Int J Radiat Oncol Biol Phys 2006, 64(2):650-656. 10.1016/j.ijrobp.2005.09.043, 16414376.
22. Matsufuji N, Fukumura A, Komori M, Kanai T, Kohno T. Influence of fragment reaction of relativistic heavy charged particles on heavy-ion radiotherapy. Phys Med Biol 2003, 48(11):1605-1623. 10.1088/0031-9155/48/11/309, 12817941.
23. Matsufuji N, Kanai T, Kanematsu N, Miyamoto T, Baba M, Kamada T, Kato H, Yamada S, Mizoe JE, Tsujii H. Specification of Carbon Ion Dose at the National Institute of Radiological Sciences (NIRS). J Radiat Res(Tokyo) 2007, 48(Suppl A):A81-A86.
24. Canman CE, Chen CY, Lee MH, Kastan MB. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harb Symp Quant Biol 1994, 59:277-286.
25. Canman CE, Kastan MB. Role of p53 in apoptosis. Adv Pharmacol 1997, 41:429-460.
26. Canman CE, Wolff AC, Chen CY, Fornace AJ, Kastan MB. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 1994, 54(19):5054-5058.
27. Gueven N, Becherel OJ, Birrell G, Chen P, DelSal G, Carney JP, Grattan-Smith P, Lavin MF. Defective p53 response and apoptosis associated with an ataxia-telangiectasia-like phenotype. Cancer Res 2006, 66(6):2907-2912. 10.1158/0008-5472.CAN-05-3428, 16540636.
28. Crawford LV, Pim DC, Gurney EG, Goodfellow P, Taylor-Papadimitriou J. Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein. Proc Natl Acad Sci USA 1981, 78(1):41-45. 10.1073/pnas.78.1.41, 318985, 6264441.
29. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T, Kaakaji R, Peterson JW, Werbel B, Barnett GH. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 1996, 13(6):1279-1285.
30. Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23(13):2330-2338. 10.1038/sj.onc.1207396, 14743206.
31. Naka T, Boltze C, Kuester D, Schulz TO, Schneider-Stock R, Kellner A, Samii A, Herold C, Ostertag H, Roessner A. Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression. Cancer 2005, 104(6):1255-1263. 10.1002/cncr.21296, 16078265.
32. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760. 10.1038/nature05236, 17051156.
33. Kruuv J, Sinclair WK. X-ray sensitivity of synchronized Chinese hamster cells irradiated during hypoxia. Radiat Res 1968, 36(1):45-54. 10.2307/3572536, 17387925.
34. Park SA, Kim HS. F-18 FDG PET/CT evaluation of sacrococcygeal chordoma. Clin Nucl Med 2008, 33(12):906-908. 10.1097/RLU.0b013e31818c4e88, 19033806.
35. Brurberg KG, Skogmo HK, Graff BA, Olsen DR, Rofstad EK. Fluctuations in pO2 in poorly and well-oxygenated spontaneous canine tumors before and during fractionated radiation therapy. Radiother Oncol 2005, 77(2):220-226. 10.1016/j.radonc.2005.09.009, 16257074.
36. Cooper RA, Carrington BM, Loncaster JA, Todd SM, Davidson SE, Logue JP, Luthra AD, Jones AP, Stratford I, Hunter RD, West CM. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000, 57(1):53-59. 10.1016/S0167-8140(00)00259-0, 11033189.
37. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77(1):18-24. 10.1016/j.radonc.2005.06.038, 16098619.
38. Davis MA, Little JB. RBE and OER of the heavy ionizing particles released during 10beta-neutron capture therapy. Rev Latino am Microbiol Parasitol (Mex) 1968, 10(2):207.
39. Bassler N, Jakel O, Sondergaard CS, Petersen JB. Dose- and LET-painting with particle therapy. Acta Oncol 2010, 49(7):1170-1176. 10.3109/0284186X.2010.510640, 20831510.
40. Tsujii H, Mizoe J, Kamada T, Baba M, Tsuji H, Kato H, Kato S, Yamada S, Yasuda S, Ohno T, Yanagi T, Imai R, Kagei K, Hara R, Hasegawa A, Nakajima M, Sugane N, Tamaki N, Takagi R, Kandatsu S, Yoshikawa K, Kishimoto R, Miyamoto T. Clinical Results of Carbon Ion Radiotherapy at NIRS. J Radiat Res(Tokyo) 2007, 48(Suppl A):A1-A13.